The Price Is Right For Oxford Nanopore Technologies plc (LON:ONT)
Dec 19
Have your own idea? Try our Stock Screener
U.K. (FTSE) Life Sciences Industry Analysis
UpdatedJan 17, 2025
DataAggregated Company Financials
Companies9
- 7D7.8%
- 3M3.6%
- 1Y-11.9%
- YTD12.5%
In the last week, the Life Sciences industry is up 7.8%, with Oxford Nanopore Technologies up 11%. In the same time, Fusion Antibodies was down 14%. In the past year, the industry is down 12%. As for the next few years, earnings are expected to grow by 24% per annum.
Industry Valuation and Performance
Has the U.K. Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 17 Jan 2025 | UK£2.1b | UK£307.6m | -UK£196,033,516.80 | 7.1x | -10.7x | 6.8x |
| Sun, 15 Dec 2024 | UK£2.1b | UK£306.4m | -UK£195,163,702.56 | 8.5x | -10.8x | 6.9x |
| Tue, 12 Nov 2024 | UK£1.9b | UK£305.1m | -UK£193,004,299.12 | 11.1x | -10x | 6.3x |
| Thu, 10 Oct 2024 | UK£2.0b | UK£304.4m | -UK£192,350,536.90 | 10.3x | -10.6x | 6.7x |
| Sat, 07 Sep 2024 | UK£2.0b | UK£293.4m | -UK£192,317,721.90 | 12.2x | -10.4x | 6.8x |
| Mon, 05 Aug 2024 | UK£1.8b | UK£295.5m | -UK£189,945,748.23 | 12.6x | -9.7x | 6.2x |
| Wed, 03 Jul 2024 | UK£1.5b | UK£295.9m | -UK£190,219,269.39 | 11.5x | -7.9x | 5.1x |
| Fri, 31 May 2024 | UK£1.6b | UK£295.6m | -UK£189,825,740.04 | 11.3x | -8.5x | 5.5x |
| Sun, 28 Apr 2024 | UK£1.5b | UK£292.9m | -UK£189,020,345.45 | 7254.7x | -7.7x | 5x |
| Tue, 26 Mar 2024 | UK£1.8b | UK£295.9m | -UK£213,186,589.21 | 7352.9x | -8.3x | 6x |
| Thu, 22 Feb 2024 | UK£1.9b | UK£285.9m | -UK£189,294,445.63 | 6961.7x | -9.9x | 6.6x |
| Sat, 20 Jan 2024 | UK£2.9b | UK£450.2m | -UK£176,590,140.00 | 62.1x | -16.2x | 6.4x |
| Mon, 18 Dec 2023 | UK£3.1b | UK£450.1m | -UK£174,093,562.00 | 54.8x | -17.6x | 6.8x |
| Wed, 15 Nov 2023 | UK£3.0b | UK£455.7m | -UK£168,812,508.00 | 48.6x | -17.9x | 6.6x |
| Fri, 13 Oct 2023 | UK£3.0b | UK£458.6m | -UK£165,609,758.00 | 52.7x | -18x | 6.5x |
| Sun, 10 Sep 2023 | UK£3.1b | UK£440.5m | -UK£166,985,165.00 | 69.6x | -18.6x | 7x |
| Tue, 08 Aug 2023 | UK£3.4b | UK£476.5m | -UK£124,657,875.00 | 70.6x | -27x | 7.1x |
| Thu, 06 Jul 2023 | UK£2.9b | UK£476.6m | -UK£124,781,543.00 | 66.1x | -23.6x | 6.2x |
| Sat, 03 Jun 2023 | UK£3.3b | UK£476.9m | -UK£116,967,761.00 | 67.8x | -28.4x | 7x |
| Mon, 01 May 2023 | UK£3.1b | UK£479.9m | -UK£117,165,188.00 | 36.3x | -26.8x | 6.5x |
| Wed, 29 Mar 2023 | UK£2.7b | UK£459.0m | -UK£119,147,500.00 | 33.4x | -22.8x | 5.9x |
| Fri, 24 Feb 2023 | UK£3.2b | UK£443.8m | -UK£183,166,505.00 | 44.1x | -17.2x | 7.1x |
| Sun, 22 Jan 2023 | UK£3.4b | UK£442.7m | -UK£182,486,738.00 | 47.5x | -18.6x | 7.7x |
| Tue, 20 Dec 2022 | UK£3.4b | UK£443.3m | -UK£182,823,312.00 | 48.3x | -18.3x | 7.6x |
| Thu, 17 Nov 2022 | UK£3.8b | UK£447.6m | -UK£178,735,500.00 | 50.2x | -21x | 8.4x |
| Sat, 15 Oct 2022 | UK£67.9b | UK£449.2m | -UK£176,568,208.00 | 42.7x | -384.3x | 151x |
| Mon, 12 Sep 2022 | UK£3.8b | UK£366.0m | -UK£191,147,579.00 | 47.3x | -20x | 10.5x |
| Wed, 10 Aug 2022 | UK£3.9b | UK£366.6m | -UK£188,072,427.00 | 47.7x | -20.7x | 10.6x |
| Fri, 08 Jul 2022 | UK£3.8b | UK£366.8m | -UK£188,165,802.00 | 41.2x | -20.4x | 10.5x |
| Sun, 05 Jun 2022 | UK£3.8b | UK£360.3m | -UK£192,190,085.00 | 43x | -19.9x | 10.6x |
| Tue, 03 May 2022 | UK£5.2b | UK£922.8m | -UK£165,792,855.00 | 45.1x | -31.3x | 5.6x |
| Thu, 31 Mar 2022 | UK£6.8b | UK£929.6m | -UK£311,055,360.00 | 48.1x | -21.9x | 7.3x |
| Sat, 26 Feb 2022 | UK£7.0b | UK£891.3m | -UK£199,679,897.00 | 43.5x | -35.3x | 7.9x |
| Mon, 24 Jan 2022 | UK£8.0b | UK£849.0m | -UK£184,521,973.00 | 30.4x | -43.4x | 9.4x |
Price to Earnings Ratio
-43.4x
Current Industry PE
- Investors are pessimistic on the British Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 8.3x is higher than the industry's current PS ratio of 6.8x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have deteriorated over the last three years.
- Revenues have also declined 29% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Trends
Which industries have driven the changes within the U.K. Healthcare industry?
| GB Market | 0.96% | |
| Healthcare | -0.61% | |
| Life Sciences | 7.81% | |
| Clinical Research and Equipment | 7.81% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ONT Oxford Nanopore Technologies | UK£1.47 | 10.5% +UK£133.7m | -10.0% | PS8.4x | |
| MXCT MaxCyte | UK£3.83 | 5.8% +UK£22.2m | -7.2% | PS10.9x | |
| PRM Proteome Sciences | UK£0.042 | 21.6% +UK£2.2m | -7.3% | PS3x | |
| PYC Physiomics | UK£0.0088 | 6.1% +UK£101.6k | -48.5% | PS3.1x |